This is a working overview of reversed-phase HPLC, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-09-08. Anything still debated is marked as such rather than presented as settled.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.
Lyophilised melanotan-2 is supplied as a solid, which is more stable than a solution. The material is hygroscopic, so weighing is done quickly, in low humidity, with the container kept sealed. Reconstitution usually uses water for injection or bacteriostatic water, added down the wall of the vial to limit foaming. A reconstituted solution is held at 2 to 8 °C and kept away from light. Repeated freezing and thawing of the same vial is avoided because ice crystal formation and concentration effects degrade the peptide.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analog of alpha-melanocyte-stimulating hormone |
| Primary receptor family | Melanocortin receptors MC1R through MC5R | Binding is not subtype-selective |
| Development period | 1980s | Synthesized during pigmentation and appetite research |
| Regulatory status | Not an approved medicine | No major regulator has authorized human use |
| Related compound | Afamelanotide | Linear analog studied for photoprotection |
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Freeze-dried melanotan-2 is normally kept as a desiccated powder at minus twenty degrees Celsius or lower, shielded from light and moisture. Peptides of this size degrade through hydrolysis, oxidation and deamidation, and each pathway accelerates as temperature and water activity rise. Repeated freeze-thaw cycles promote aggregation and loss of material, so aliquoting a stock solution before freezing is standard laboratory practice. Once dissolved, the solution is markedly less stable than the powder. In laboratory work, solutions are generally refrigerated and used within days rather than kept for months.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or oxidised impurities. Mass spectrometry, most often coupled to liquid chromatography, confirms molecular mass and detects substitutions that chromatography alone may miss. Amino acid analysis and peptide mapping supply additional structural evidence, while nuclear magnetic resonance is reserved for full structural confirmation. Laboratories that examine samples sold online report wide variation in actual content, with some vials containing little or none of the labelled material.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The peptide was developed during the 1980s by researchers investigating melanocortin signalling and skin pigmentation pathways. Early work focused on analogues of alpha-melanocyte-stimulating hormone that would resist enzymatic breakdown more effectively than the parent molecule. Melanotan-2 emerged from that programme as a shortened, cyclised variant. Reports describing its synthesis and receptor activity later appeared in the scientific literature. Commercial availability grew through unregulated channels rather than through pharmaceutical approval.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Embryonic Hb are expressed as early as four to six weeks of embryogenesis and disappear around the eighth week of gestation as they are replaced by fetal Hb. Embryonic Hbs include: Hb Gower-1, composed of two ζ (zeta) globins and two ε (epsilon) globins, i.e., ζ2ε2 Hb Gower-2, composed of two α globins and two ε globins (α2ε2) Hb Portland, composed of two ζ globins and two γ (gamma) globins (ζ2γ2) Fetal Hb (HbF) is produced from approximately eight weeks of gestation through birth and constitutes approximately 80 percent of Hb in the full-term neonate. It declines during the first few months of life and, in the normal state, constitutes <1 percent of total Hb by early childhood. HbF is composed of two α globins and two γ globins (α2γ2). Adult Hb (HbA) is the predominant Hb in children by six months of age and onward; it constitutes 96-97% of total Hb in individuals without a hemoglobinopathy. It is composed of two α globins and two β globins (α2β2). HbA2 is a minor adult Hb that normally accounts for approximately 2.5–3.5% of total Hb from six months of age onward. It is composed of two α globins and two δ (delta) globins (α2δ2).
== Side effects and withdrawal from market == On April 7, 2005, Pfizer withdrew Bextra from the U.S. market on recommendation by the FDA, citing an increased risk of heart attack and stroke and also the risk of a serious, sometimes fatal, skin reaction. This was a result of recent attention to prescription NSAIDs, such as Merck's Vioxx. Other reported side effects were angina and Stevens–Johnson syndrome. Pfizer first acknowledged cardiovascular risks associated with Bextra in October 2004. The American Heart Association soon after was presented with a report indicating patients using Bextra while recovering from heart surgery were 2.19 times more likely to suffer a stroke or heart attack than those taking placebos. In a large study published in The Journal of the American Medical Association in 2006, valdecoxib appeared less adverse for renal (kidney) disease and heart arrhythmia compared to Vioxx, but elevated renal risks were slightly suggested.
Narrated by Julie Berry, produced by Jeremy Bugler, directed by Richard Klein, made by Fulmar Television & Film 4 September Walking on Water, about surfing, with Ken Bradshaw, Edward Coventry, Viscount Deerhurst; Waimea Bay has the largest ridable waves in the world, with 50 feet waves; the waves originate from Japan; Mark Foo, who later drowned that year at Mavericks, California; Huntington Beach, California, known as Surf City. Directed by Steve Stevenson, produced by Mike Wallington, made by Parvenu Productions 11 September The Cyborg Cometh, Austrian Manfred Clynes invented the term cyborg for NASA in the 1950s; Prof Donna Haraway, author of the 1985 A Cyborg Manifesto; the nascent internet, and SF Net; Mike Browne, who had a skiing accident in 1993 making him paraplegic, the founder of Snow and Rock, now owned by Cotswold Outdoor; Lisa Jean Moore, the semen industry, techno-semen, and The Sperm Bank of California; prenatal testing; David Bentley of the MRC's Human Genome Mapping Project at the Sanger Centre (now the Wellcome Sanger Institute).
== Sample preparation == LAMMA is particular about the sample which is used. The sample must be small and thin. Ionization of too much material results in a large microplasma whose time spread and ion energy distribution entering the mass spectrometer can result in undesired peak deformation.
==== Reproducibility ==== In 1989, after Fleischmann and Pons had made their claims, many research groups tried to reproduce the Fleischmann-Pons experiment, without success. A few other research groups, however, reported successful reproductions of cold fusion during this time. In July 1989, an Indian group from the Bhabha Atomic Research Centre (P. K. Iyengar and M. Srinivasan) and in October 1989, John Bockris' group from Texas A&M University reported on the creation of tritium. In December 1990, professor Richard Oriani of the University of Minnesota reported excess heat. Groups that did report successes found that some of their cells were producing the effect, while other cells that were built exactly the same and used the same materials were not. Researchers who continued to work on the topic have claimed over the years that many successful replications had been made, but still had problems getting reliable replications. Reproducibility is one of the main principles of the scientific method, and its lack led most physicists to believe that the few positive reports could be attributed to experimental error. The DOE 2004 report said among its conclusions and recommendations:
Sources: en.wikipedia.org
== Chimerism and intersex == The concept of a "human hermaphrodite" resulting from chimerism is largely a misconception. Most intersex individuals are not chimeras, and most human chimeras are not observed to have intersex traits. Theoretically, if a gynandromorphic human chimera were to have fully functioning male and female gonad tissue, such an individual could self-fertilize; this hypothesis is backed by the fact that hermaphroditic animal species commonly reproduce in this way, and it has been observed in a rabbit. However, no such case of functional self-fertilization has ever been documented in humans; and it is non-existent or extremely rare in mammals, especially in humans. While humans are known to have sex characteristics that diverge from typical males or typical females, these individuals fall under the social umbrella of intersex conditions and traits, and some consider the term "hermaphrodite" to be a slur when applied to them.
Sickle cell anemia: a genetic disorder where abnormal hemoglobin (HbS) causes red blood cells to become rigid and sickle-shaped, leading to intermittent blood vessel blockages, hemolysis, and tissue ischemia. Destruction of these defective red blood cells results in anemia, which stimulates the bone marrow to increase red blood cell production. Because of this, reticulocytosis is a possible lab finding in sickle cell disease. Hereditary spherocytosis: a genetic disorder where defects in red blood cell membrane proteins cause them to lose their normal shape, becoming spherical (spherocytes) which are prone to getting stuck and rupturing in the spleen. This hemolysis creates a chronic shortage of red blood cells, stimulating the bone marrow to increase production and release reticulocytes into circulation. Glucose-6-phosphate dehydrogenase (G6PD) deficiency: a genetic disorder that makes red blood cells vulnerable to oxidative stress. When individuals with this deficiency consume fava beans, experience stress or are exposed to certain medications, oxidative damage leads to red blood cell destruction (hemolysis). In response to this rapid hemolysis, the bone marrow increases RBC production, resulting in reticulocytosis as it attempts to replace the destroyed cells. Autoimmune hemolytic anemia: caused by the host immune system attacking and destroying its own red blood cells. In response to this, the bone marrow will begin to produce more red blood cells to compensate for this destruction.
Gas: Volatile vapors often used for fuel. Charcoal: The solid carbon residue remaining in the kiln. Liquid distillate: The condensed vapors that form the basis for further refinement. Separation of the liquid: The liquid distillate naturally separates (or is processed) into two distinct layers:
==== HIV protease binding ==== Ritonavir is a pseudo-C2-symmetric peptidomimetic inhibitor of the HIV-1 protease. It acts as a tight-binding, active-site titrant with an inhibition constant (Ki) of 15 pM. At a structural level, the P3 isopropylthiazolyl group of ritonavir projects directly into the enzyme's active site to form critical hydrophobic interactions with the side chain of the Valine-82 (V82) residue. Resistance to ritonavir occurs when the viral protease gene develops mutations that distort this binding pocket; these amino acid substitutions generally occur in a stepwise fashion at specific positions, including V82A, V82F, V82T, and V82S.
Sources: en.wikipedia.org
Tonic water is often used as a drink mixer for cocktails, especially gin and tonic. Vodka tonic is also popular. Tonic water with lemon or lime juice added is often known as bitter lemon or bitter lime. It is popular for its signature bittersweet taste. Another use of tonic water is in coffee. The espresso and tonic was created in Helsingborg, Sweden, at Koppi Roasters after a staff party where they mixed tonic water, syrup, and an espresso. Since 2007, the drink has grown in popularity in Scandinavia, Europe, and the United States.
=== Cystatin C === Problems with creatinine (varying muscle mass, recent meat ingestion (much less dependent on the diet than urea), etc.) have led to evaluation of alternative agents for estimation of GFR. One of these is cystatin C, a ubiquitous protein secreted by most cells in the body (it is an inhibitor of cysteine protease). Cystatin C is freely filtered at the glomerulus. After filtration, Cystatin C is reabsorbed and catabolized by the tubular epithelial cells, with only small amounts excreted in the urine. Cystatin C levels are therefore measured not in the urine, but in the bloodstream. Equations have been developed linking estimated GFR to serum cystatin C levels. Most recently, some proposed equations have combined sex, age, adjusted cystatin C and creatinine. In 2022, the National Kidney Foundation (NKF) and American Society of Nephrology (ASN)'s Joint Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Diseases recommended national efforts to facilitate increased, routine, and timely use of cystatin C. They noted that cystatin C would be useful particularly to confirm estimated GFR in adults who are at risk for or have chronic kidney disease. They suggested that combining filtration markers (creatinine and cystatin C) is more accurate and would support better clinical decisions than either marker alone.
Pakistani officials attributed several of these attacks to militant groups operating from Afghan territory and warned that military action could follow if the Taliban did not act against these groups. On 11 February 2026, Pakistani Defence Minister Khawaja Asif warned that Pakistan may take action against militants in Afghanistan before the start of the Islamic month of Ramadan if the Taliban failed to deter militant activities from the territory under their control. Following further attacks in February, Pakistani officials signalled that their restraint had been exhausted, setting the stage for the airstrikes that began the conflict.
Sources: en.wikipedia.org
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.
Afamelanotide is a linear analog that has received approval in some jurisdictions for a specific photoprotection indication. Melanotan II is cyclic and less selective across melanocortin receptors. The two are related but are not interchangeable in regulatory or clinical terms.
A compound that activates several receptor subtypes may produce effects beyond pigmentation. Selectivity influences which tissues respond and shapes the side-effect profile described in reports. Designing subtype-selective analogs is a stated goal of melanocortin research.
Low temperature slows hydrolysis and oxidation, the two main routes by which the peptide backbone and side chains are modified. A lyophilised powder stored at −20 °C is more stable than one kept at room temperature, and once the material is dissolved the degradation rate rises, making refrigeration more important.